TBB

CAS No. 17374-26-4

TBB( NSC 231634 | Tetrabromobenzotriazole )

Catalog No. M12636 CAS No. 17374-26-4

TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
5MG 36 In Stock
10MG 51 In Stock
25MG 65 In Stock
50MG 75 In Stock
100MG 114 In Stock
200MG 166 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TBB
  • Note
    Research use only, not for human use.
  • Brief Description
    TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).
  • Description
    TBB(NSC 231634) is a highly selective, ATP/GTP-competitive inhibitor of casein kinase-2 (CK2)with IC50s of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively).
  • In Vitro
    Investigation of the inhibitory power of TBB with a panel of 33 protein kinases shows highest potency for CK2 (casein kinase 2) (human CK2: IC50=1.6 μM at 100 μM ATP). TBB also inhibits three other kinases with less potency: CDK2 (IC50=15.6 μM), phosphorylase kinase (IC50=8.7 μM) and glycogen synthase kinase 3β (GSK3β) (IC50=11.2 μM). All other kinases tested have IC50 values 50-fold greater than that for CK2. The viability of the androgen insensitive PC-3 cells may be diminished by TBB (60 μM TBB) acting either alone or combined with anticancer agents CPT or TRAIL when a proper time schedule of the administration is applied. The time schedule-dependent activity of TBB does not come from its effect on apoptosis in PC-3 cells. TBB is an ATP/GTP competitive inhibitor of protein kinase casein kinase-2 (CK2), has been examined against a panel of 33 protein kinases, either Ser/Thr- or Tyr-specific. In the presence of 10 μM TBB (and 100 μM ATP) only CK2 is drastically inhibited (>85%) whereas three kinases (phosphorylase kinase, glycogen synthase kinase 3L and cyclin-dependent kinase 2/cyclin A) underwent moderate inhibition, with IC50 values one-two orders of magnitude higher than CK2 (IC50=0.9 μM). TBB also inhibits endogenous CK2 in cultured Jurkat cells.
  • In Vivo
    The extent of retinal neovascularization in a mouse OIR model is reduced by approximately 60% after treatment with TBB (6 days at 60 mg/kg per day).
  • Synonyms
    NSC 231634 | Tetrabromobenzotriazole
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CK2| CDK2| GSK-3β
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    17374-26-4
  • Formula Weight
    434.71
  • Molecular Formula
    C6HBr4N3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO, Ethanol: 100 mM
  • SMILES
    BrC1=C(NN=N2)C2=C(Br)C(Br)=C1Br
  • Chemical Name
    4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Orzechowska E, et al. Oncol Rep. 2012 Jan;27(1):281-5.
molnova catalog
related products
  • CDK7 and 9 inhibitor...

    A potent, selective transcriptional CDK inhibitor with Ki of 2.3 and 0.38 nM for CDK7 and CDK9, respectively; displays >30-fold selectivity over CDK1/2/4, inhibits VEGFR2 with IC50 of 180 nM in a panel of non-CDK kinases.

  • KB-0742 dihydrochlor...

    KB-0742 dihydrochloride is a potent, selective and orally inhibitor of ?CDK9.

  • BAY-958

    BAY-958 (BAY958, LDC526)?is a potent, selective PTEFb/CDK9 inhibitor with IC50 of 5 nM against CDK9/CyclinT1.